Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy

• Published in: Clinical genitourinary cancer 2021-08, Vol.19 (4), p.296-304.e3
• Main Authors: Tward, Jonathan D., Schlomm, Thorsten, Bardot, Stephen, Canter, Daniel J., Scroggins, Troy, Freedland, Stephen J., Lenz, Lauren, Flake, Darl D., Cohen, Todd, Brawer, Michael K., Stone, Steven, Bishoff, Jay
• Format: Article
• Language: English
• Subjects: ADT with radiation; Androgen Antagonists - therapeutic use; Disease progression; Genomic classifier; Humans; Male; Metastasis; Multimodality therapy; Prostate-Specific Antigen; Prostatic Neoplasms - therapy; Retrospective Studies; Risk Factors
• ISSN: 1558-7673; 1938-0682
• DOI: 10.1016/j.clgc.2021.01.003

The combined clinical cell-cycle risk (CCR) score is a validated model that combines the cell-cycle progression (CCP) score with the University of California San Francisco Cancer of the Prostate Risk Assessment (CAPRA) score. This score determines the risk of progressive disease for men with prostate cancer. Here, we further validate the prognostic ability of the CCR score and evaluate its ability to help determine which patients may safely forgo multimodality therapy. We evaluated the CCR and a CCR-based multimodality threshold (2.112) in a retrospective, multi-institutional cohort of men with National Comprehensive Cancer Network intermediate- or high-risk localized disease (N = 718). These men received single or multimodality therapy (androgen deprivation with radiation [RT], or surgery with adjuvant RT or hormones). CCR score prognosticated metastasis for single-modality therapy, as a continuous variable (hazard ratio, 3.97; 95% confidence interval [CI], 2.61-6.06) and when dichotomized at the threshold (hazard ratio, 15.90; 95% CI, 5.43-46.52). The 10-year Kaplan-Meier risk for those receiving single-modality (RT or surgical) therapy with CCR scores below and above the threshold for single-modality treatment was 4.3% (95% CI, 1.0%-17.1%) and 20.4% (95% CI, 13.2%-30.7%), respectively. Using the threshold, 27% of men with newly diagnosed high-risk and 73% with unfavorable intermediate-risk disease could avoid multimodality therapy. Patients with CCR scores below the multimodality threshold (2.112) may safely forgo multimodality therapy. The CCR score can be used as a decision aid to counsel men whether or not single-modality therapy would be sufficient for their intermediate- or high-risk prostate cancer. •A CCR score prognosticated metastasis better than risk group.•A score threshold determines who can be safely treated with a single modality.•The score can determine the absolute benefit of multimodality therapy. Using a retrospective, multi-institutional cohort of men with prostate cancer (N = 718), this study evaluated a score that combines a genome expression classifier and clinical information to prognosticate progression to metastatic disease in various treatment contexts. A score threshold identified men with intermediate- and high-risk prostate cancer who could safely forgo multimodal therapy.